Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Huirong Chang"'
Autor:
Lingzhi Yan, Su Qu, Jingjing Shang, Xiaolan Shi, Liqing Kang, Nan Xu, Mingqing Zhu, Jin Zhou, Song Jin, Weiqin Yao, Ying Yao, Guanghua Chen, Huirong Chang, Xiaming Zhu, Lei Yu, Depei Wu, Chengcheng Fu
Publikováno v:
Cancer Medicine, Vol 10, Iss 2, Pp 563-574 (2021)
Abstract The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T‐cell (CART) treatment is yet to be optimized. This study aims to investigate the safet
Externí odkaz:
https://doaj.org/article/ad2f138e95ce43a69f64c1a09ab73154
Autor:
Xiaolan Shi, Lingzhi Yan, Jingjing Shang, Liqing Kang, Zhi Yan, Song Jin, Mingqing Zhu, Huirong Chang, Feiran Gong, Jiazi Zhou, Guanghua Chen, Jinlan Pan, Dandan Liu, Xiaming Zhu, Fang Tang, Minghong Liu, Wei Liu, Feirong Yao, Lei Yu, Depei Wu, Chengcheng Fu
Publikováno v:
American Journal of Hematology. 97:537-547
Few prospective studies have examined posttransplant chimeric antigen receptor (CAR) T cell infusion as candidates for front-line consolidation therapy for high-risk multiple myeloma (MM) patients. This single-arm exploratory clinical trial is the fi
Autor:
Depei Wu, Xiaolan Shi, Guanghua Chen, Song Jin, Lingzhi Yan, Nan Xu, Chengcheng Fu, Xiaming Zhu, Ming-Qing Zhu, Su Qu, Ying Yao, Huirong Chang, Jin Zhou, Weiqin Yao, Jingjing Shang, Liqing Kang, Lei Yu
Publikováno v:
Cancer Medicine, Vol 10, Iss 2, Pp 563-574 (2021)
Cancer Medicine
Cancer Medicine
The low rate of durable response against relapsed and/or refractory multiple myeloma (RRMM) in recent studies indicates that chimeric antigen receptor T‐cell (CART) treatment is yet to be optimized. This study aims to investigate the safety and eff
Autor:
Lingzhi Yan, Zhi Yan, Zhu Ming-qing, Huizhu Kang, Jin Zhou, Song Jin, Xiaolan Shi, Jia-Zi Zhou, Weiqin Yao, Jingjing Shang, Yong Liu, Ying Yao, Feiran Gong, Depei Wu, Juanjuan Su, Lei Yu, Ruju Wang, Fu Cheng Cheng, Liqing Kang, Guanghua Chen, Huirong Chang
Publikováno v:
Blood. 134:1949-1949
Background: Multiple myeloma (MM) is an incurable plasma cell malignancies despite the advent of numerously new drugs especially for high risk patients. Our previous study showed good response for the de novo high risk patients who received CD19 and
Autor:
Feiran Gong, Jia-Zi Zhou, Li-Jun Dai, Huirong Chang, Zi-Ling Zhu, Yu-Feng Feng, Wei Li, Depei Wu
Publikováno v:
Cell Biochemistry and Biophysics. 73:643-647
Conventionally, serum protein electrophoresis (SPE) and serum immunofixation electrophoresis (IFE) are used as primary methods to diagnose and monitor multiple myeloma (MM). Recently, serum-free light chain (FLC) assay has been incorporated into hema
Autor:
Ying Yao, Liqing Kang, Xiaolan Shi, Yong Liu, Jin Zhou, Huirong Chang, Zi-Ling Zhu, Song Jin, Guanghua Chen, Lei Yu, Shuang Yan, Chengcheng Fu, Depei Wu, Weiqin Yao, Jingjing Shang, Su Qu, Lingzhi Yan
Publikováno v:
Blood. 132:1009-1009
Background: Multiple myeloma (MM) is an incurable plasma cell malignancies despite the advent of numerously new drugs. Survival was poor particularly for high risk patients such as R-ISS stage III. The preliminary data from our center showed that the
Autor:
Yufeng Feng, Yi Wang, Aining Sun, Zi-Ling Zhu, Xiaowen Tang, Depei Wu, Huirong Chang, Guanghua Chen, Jiannong Cen
Publikováno v:
European Journal of Haematology. 81:226-235
Graft-versus-host disease (GVHD), leukemia relapse, and immune deficiency remain the major limitations of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Donor natural killer cells (NK) and cytokines have good potential in GVHD preven
Publikováno v:
Acta haematologica. 133(1)
The management of severe late-onset hemorrhagic cystitis (LO-HC) after allogeneic hematopoietic stem cell transplantation (HSCT) is still challenging. Because mesenchymal stromal cells (MSCs) possess anti-inflammatory and tissue repair-promoting prop
Autor:
Yue Han, Qiangli Wang, Aining Sun, Xiaowen Tang, Chengcheng Fu, Huiying Qiu, Huirong Chang, Miao Miao, Depei Wu, Haiwen Huang, Zhengming Jin
Publikováno v:
Blood. 128:5845-5845
Objective: To evaluate the efficacy of auto-HSCT and allo-HSCT in the treatment of high risk peripheral T cell lymphoma (PTCL). Methods: From July 2007 to July 2014, 60 cases of high risk PTCL were analyzed retrospectively. Results: All 60 patients w
Autor:
Miao Miao, Xiaowen Tang, Yue Han, Huirong Chang, Depei Wu, Zhengming Jin, Huiying Qiu, Xiaofang Xiao, Aining Sun, Haiwen Huang, Chengcheng Fu, Jia Chen
Publikováno v:
Blood. 128:5849-5849
Purpose: The role of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) therapy for refractory or relapsed (R/R) aggressive non-Hodgkin lymphoma (NHL) patients was still unknown. In this study, we aimed to explore the clinical outcom